CAPR•benzinga•May 5, 2025 at 01:38 PM

Capricor Therapeutics Announces Completion Of Mid-Cycle Review Meeting With FDA On Deramiocel For The Treatment Of Duchenne Muscular Dystrophy Cardiomyopathy; Remains On Track For PDUFA Target Action Date Of August 31, 2025

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 5, 2025 by benzinga